Endologix (ELGX) Reports In-Line Q3 EPS

Endologix (NASDAQ: ELGX) reported Q3 EPS of ($0.17),which may note compare to the analyst estimate of ($0.17). Revenue for the quarter came in at $46 million versus the consensus estimate of $46.66 million.

Financial Guidance

Due to slower than expected AFX2 sales recovery in the U.S., Endologix is reducing its previously issued revenue guidance. The Company now anticipates 2017 revenue in the range of $181 million to $184 million, compared to the previous range of $185 million to $190 million. As a result of careful expense management, the Company is revising its operating expense guidance to a range of $165 million to $170 million, compared to the previous guidance of $170 million. The Company now expects 2017 GAAP loss per share to be in the range of $(0.91) to $(0.93), compared to the previous range of $(0.91) to $(0.95).

For earnings history and earnings-related data on Endologix (ELGX) click here.

You May Also Be Interested In